Southern Africa is moving swiftly to combat the threat of XDR-TB.
Wise
Jacqui
J
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control / Q000628:therapy; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D023801:Directly Observed Therapy; D024901:Drug Resistance, Multiple, Bacterial; D014943:Global Health; D015658:HIV Infections / Q000150:complications* / Q000628:therapy; D006801:Humans; D013019:South Africa / Q000453:epidemiology; D018088:Tuberculosis, Multidrug-Resistant / Q000150:complications / Q000517:prevention & control / Q000628:therapy*; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000517:prevention & control / Q000628:therapy*; D014944:World Health Organization
D000995:Antitubercular Agents